Highlights RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Market Closed - Nasdaq Other stock markets 02:00:01 15/05/2024 am IST			5-day change	1st Jan Change
0.4571 ^USD	-1.42%		-0.37%	-68.69%

06/05	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	MT
06/05	RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	06/05	CI
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	24/04	CI
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04	CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	11/03	MT
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	05/03	CI
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	20/02	CI
RedHill Biopharma to Seek Acquisitions	26/01	CI
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola	20/12	CI
Redhill Biopharma Says FDA Grants 5-Year Market Exclusivity for Bacterial Infection Treatment Talicia, Shares Jump Pre-Bell	27/11	MT
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034	27/11	CI
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study	03/23/03	CI
Redhill Biopharma Gets Non-Compliance Notice From Nasdaq	25/23/25	MT
Redhill Biopharma Says FDA Approved Supplemental New Drug Application for Talicia	18/23/18	MT
Redhill Biopharma Ltd. Announces Fda Snda Approval for Talicia®?	18/23/18	CI
RedHill Biopharma Ltd. Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102	05/23/05	CI
RedHill Biopharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	17/23/17	CI
RedHill Biopharma Ltd. Announces its Partner, Gaelan Medical LLC Receives Marketing Approval from United Arab Emirates Ministry of Health for Talicia	01/23/01	CI
Redhill Biopharma Ltd. Announces its RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Clears for Initiation by FDA	31/23/31	CI
Earnings Flash (RDHL) REDHILL BIOPHARMA Posts Q1 Revenue $3.6M	12/23/12	MT
RedHill Biopharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Highlights

Filters